LONDON (ShareCast) - (Sharecast News) - Bangladesh-based generic pharmaceuticals manufacturer Beximco Pharmaceuticals has started the export of blood pressure drug 'Nadolol' to the United States market, it announced on Tuesday.
The AIM-traded firm explained that Nadolol tablets, in strengths of 20mg, 40mg and 80mg, were the generic equivalent of Bristol-Myers Squibb's 'Corgard' tablets, used for treating hypertension and angina pectoris, or chest pain.

It was its fifth product for the US market, following the successful launches of 'Carvedilol', 'Sotalol', 'Methocarbamol' and 'Metformin'.

Beximco said that according to IQVIA audited data of US market, the total market for Nadolol was more than $63m in 2018.

"We are delighted to announce the launch of Nadolol, our fifth product in the US market, which demonstrates continued progress in expanding our presence in this important market," said chief executive Nazmul Hassan.

"With a strong portfolio and an attractive pipeline of products in development for the US and other regulated and emerging markets, we are well positioned to continue to achieve double-digit growth in our export business."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE